article thumbnail

National variation in ASCVD risk between Pooled Cohort Equations and PREVENT [Cardiovascular disease]

Annals of Family Medicine

Context In November 2023, the American Heart Association (AHA) released PREVENT, a new set of risk equations to calculate an individual's risk of atherosclerotic cardiovascular disease (ASCVD). Each individual was separated into clinically significant risk categories of <7.5%, 7.5-10%, Results 3,885 individuals met the criteria.

article thumbnail

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Annals of Family Medicine

Design and analysis: The study employed a comprehensive cohort design to compare individuals with T2D who were Ethiopian-born to their Israeli-born counterparts. Population: Jewish CHS members, aged 18+, diagnosed with T2D between 2000-2011, born in Israel or Ethiopia. Intervention: 10-year follow-up to track T2D outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Importance of Community Resources for Breastfeeding [Child and adolescent health]

Annals of Family Medicine

SAFE used a stratified, two-stage, clustered design to obtain a nationally representative sample of mothers of infants; mothers were enrolled from 32 US birth hospitals, January 2011-March 2014. Looking beyond the individual and supporting healthy communities will be critical to improve US breastfeeding rates.

Community 130
article thumbnail

President Biden Gives the Green Light for Significant Marijuana Reform

FDA Law Blog

The president’s first step was a pardon of all prior federal offenses of simple marijuana possession and a direction to the Attorney General to develop an administrative process to issue certificates of pardon to eligible individuals. HHS has undertaken scientific and medical evaluations of marijuana in recent years.

Medical 105
article thumbnail

Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS

FDA Law Blog

2011), here , and United States v. Now, after an unfavorable HHS Office of the Inspector General (OIG) advisory opinion and two defeats in court, Pfizer has appealed the Second Circuit’s decision to the Supreme Court. At the center of Pfizer’s argument is whether an AKS violation requires corrupt intent. Background. Borrasi, 639 F.3d

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Moreover, center patients not only in discussions about individual decision-making but in constructing and drawing meaning from the research. Tsai has seen race-based medicine play out in clinical practice 10:45 What role should race play in making clinical decisions?

Clinic 52
article thumbnail

Texas invests $50M in psychedelic drug research to treat addiction

Medical Xpress

The goal is to support clinical trials and bring in another $50 million in private investment to help ibogaine win approval from the U.S. Food and Drug Administration (FDA). The process could take years. Ibogaine is made from the root of a plant found in Africa. It has been banned in the U.S. Former Texas Gov.